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Abstract By co-immunoprecipitation analysis, we demon-
strated that wt-p53 formed a complex with non-structural
protein (NS) 3 of hepatitis C virus, both in the absence and the
presence of NS4A, a viral cofactor that strongly associates with
NS3. Deletional analysis revealed that a portion near the N-
terminus of NS3 (amino acids (aa) 1055 and 1200), which is
different from the NS4A binding site, was necessary for the
complex formation with wt-p53. On the other hand, a portion
near the C-terminus of wt-p53 (aa 301^360), which has been
reported to contain the oligomerization domain, was important
for the complex formation with NS3.
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1. Introduction
Hepatitis C virus (HCV), a member of the Flaviviridae fam-
ily, is an enveloped virus, whose genome is single-strand, pos-
itive-sense RNA of approximately 9.5 kb. The HCV genome
encodes a polyprotein consisting of about 3010^3033 amino
acid (aa) residues. This polyprotein has been shown to be
cleaved co- and post-translationally into mature viral proteins,
which are arranged in the order of NH2-C-E1-E2-p7-NS2-
NS3-NS4A-NS4B-NS5A-NS5B-COOH [1^3]. The function
of certain HCV proteins has been determined. For example,
a polyprotein encompassing NS2 and an N-terminal portion
of NS3 functions as metalloproteinase to autocatalytically
cleave o¡ NS3 [1]. The processed NS3 then possesses serine
proteinase activity at its N-terminal portion [2] and RNA
helicase activity at its C-terminal portion [3,4]. NS4A is
known to be a cofactor for NS3, which augments the serine
proteinase activity [5^8]. Also, NS5B is thought to be an
RNA-dependent RNA polymerase [9].
HCV causes either acute or chronic persistent infection,
with the latter potentially leading to liver cirrhosis and hep-
atocellular carcinoma [10,11]. The viral genome and antigens
have been detected in a¡ected liver cells [12,13]. Recently, it
was reported that NS3 [14] or core protein [15] might be
involved in malignant transformation of NIH3T3 cells. We
previously reported that a C-terminally truncated form of
NS3 inhibited actinomycin D-induced apoptosis possibly
through an inhibition of p53 accumulation [16] and that
NS3 was co-localized with p53 upon co-expression [17]. These
results suggest that NS3 might interact with the wild-type
(wt)-p53 tumor suppressor to inhibit apoptosis. In this study,
we examined the possible association between NS3 and wt-
p53 by using vaccinia virus-T7 hybrid expression system. Im-
munoprecipitation analysis revealed that NS3 formed a com-
plex with wt-p53 through an N-terminal portion of NS3 and a
C-terminal portion of wt-p53. It was also demonstrated that
the complex formation between NS3 and wt-p53 took place
even in the presence of NS4A. The functional implication of
their association in carcinogenesis is discussed.
2. Materials and methods
2.1. Construction of expression plasmids
Construction of NS3 and NS4A expression plasmids, pBSns3/1027^
1657, pBSns3/1027^1459, pBSns3/1201^1459, and pBSns4A/1658^
1711 (see Fig. 1A), was described previously [17,18]. To obtain
pBSns3/1027^1245 FLAG, pBSns3/1027^1459 was digested with
NdeI and BamHI and ligated to an oligonucleotide encoding the pep-
tide FLAG (DYKDDDDK). To obtain pBSns3/1055^1459 and
pBSns3/1055^1200FLAG, the corresponding portions were ampli¢ed
from pBSns3/1027^1459 by using two sets of primers NS3-S1/NS3-R1
and NS3-1/NS3-R2, respectively (Table 1). The amplicons were subcl-
oned into the unique EcoRI site, or EcoRI and BamHI sites, respec-
tively, of pBlueScript II SK3 (Stratagene). A series of deletion mu-
tants of wt-p53 were obtained as described below. First, the XhoI
fragment of pCDM8VAarg/neo, which encodes the full-size wt-p53
(p53F), was ligated to XhoI-treated pBlueScript II SK3 (Stratagene)
to generate pBS53/1^393 (Fig. 1B). To obtain pBS53/40^393, the cor-
responding portion was ampli¢ed from pBS53/1^393 by using primer
53-S1 and 53-R1 (Table 1). To obtain pBS53/1^360, pBS53/1^318 and
pBS53/1^300, corresponding portions were each ampli¢ed from
pBS53/1^393 by using sets of primers 53-S2/53-R2, 53-S2/53-R3,
and 53-S2/53-R4, respectively. These PCR products were digested
with EcoRI and XhoI and inserted into the EcoRI and XhoI sites of
pBlueScript II SK3.
2.2. Transient expression by vaccinia virus-T7 hybrid expression system
HeLa cells were used in this study unless otherwise stated. Cells
were infected with a recombinant vaccinia virus expressing T7 RNA
polymerase (vTF7-3) [19]. After 1 h, the cells were transfected with the
expression plasmids using Lipofectin reagent (Life Technologies) ac-
cording to the manufacturer’s protocol. After cultivation for 16 h, the
cells were analyzed for the complex formation of the expressed pro-
teins, as described below.
2.3. Immunoprecipitation analysis
Cells transfected with the plasmids were labeled at 12 h postinfec-
tion with 25 WCi of 35S-translabel (Amersham) per ml in serum-free
medium. Cell lysates were prepared in RIPA bu¡er consisting of 150
mM NaCl, 0.5% Triton X-100, and 10 mM Tris-HCl (pH 7.5). After
being clari¢ed by centrifugation, the cell lysates were incubated for 1 h
at 4‡C with either one of the anti-NS3, anti-p53 (clone 421; Oncogene
Science) or anti-FLAG M2 monoclonal antibodies (Kodak) and 10 Wl
of protein G/protein A Sepharose (Oncogene Science). After being
washed six times with RIPA bu¡er, the immunoprecipitates were sub-
jected to SDS-PAGE and visualized by using BAS2000 system.
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3. Results and discussion
3.1. NS3 forms a complex with wt-p53
By immuno£uorescence analysis in vaccinia virus-T7 hybrid
expression system, we previously demonstrated that NS3F
and NS3vC, but not NS3vNvC, were each co-localized with
wt-p53 [17]. In the present study, we examined the possible
complex formation between NS3 and p53 by immunoprecipi-
tation analysis. In the initial experiment, we used NS3F,
NS3vC and NS3vNvC-1 (the same as NS3vNvC in the pre-
vious study) (Fig. 1). Each form of NS3 was co-expressed with
the full-size wt-p53 (p53F) in HeLa cells. Immunoprecipita-
tion analysis was performed using anti-NS3 monoclonal anti-
body, anti-p53 monoclonal antibody or control IgG. Anti-
NS3 monoclonal antibody co-precipitated wt-p53 with NS3F
and NS3vC, but not with NS3vNvC-1 (Fig. 2A^C, lane 2).
Likewise, anti-p53 monoclonal antibody co-precipitated NS3F
and NS3vC, but not NS3vNvC-1, with wt-p53 (Fig. 2A^C,
lane 3). Thus, NS3 was likely to form a complex with wt-p53
through an N-terminal portion of NS3 (aa 1027^1200). This
portion has been shown to contain interaction domains for
NS4A [6^8,11] and NS5B [20].
HeLa cells have been reported to express the E6 and E7
oncoproteins of human papilloma virus [21], the former of
which can interact with wt-p53 [22]. To exclude the possibility
that the complex formation between NS3 and wt-p53 was
in£uenced by the E6 protein expressed in HeLa cells, we per-
formed the experiments using BHK-21 cells. Practically the
same results as those in Fig. 2 were obtained with BHK-21
cells (data not shown), suggesting that the E6 protein has
nothing to do with the observed complex formation between
NS3 and wt-p53.
We previously reported that a mutant-type (mt)-p53, which
was localized exclusively in the cytoplasm, inhibited the nu-
clear localization of NS3F and NS3vC [17,18]. We then ex-
amined their possible interaction by immunoprecipitation
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Fig. 1. Schematic representation of the open reading frame encoding full-size and N- and/or C-terminally deleted forms of NS3 and wt-p53.
A: NS3. B: wt-p53. Various functional domains are shown on the top. The numbers indicate amino acid positions.
Table 1
Nucleotide sequences of primers used in this study
Designation Nucleotide sequencea Enzyme
NS3-S1 5P-CCGGGAATTCAACATGGTCGAGGGAGAGGTTCAGG-3P EcoRI
NS3-R1 5P-GTCGAATTCCTAGGTGACACATGTGTTACA-3P EcoRI
NS3-R2 5P-TGTCGGATCCTCACTTGTCATCGTCGTCCTTGTAGTCGGACTCTACGGGCACAAAGTCCACCGCCTT-3P BamHI
53-S1 5P-GCCGCTCGAGGCAATGGATGATTTGATGCTGTCCC-3P XhoI
53-R1 5P-GTGGGAATTCTCAGTCTGAGTCAGGCCCTTCTGT-3P EcoRI
53-S2 5P-AGCCCTCGAGCCTTCCGGGTCACTGCCATGGAGG-3P XhoI
53-R2 5P-GAGCGAATTCCTACCCTGGCTCCTTCCCAGCCTG-3P EcoRI
53-R3 5P-CCAGGAATTCCTACTTTGGCTGGGGAGAGGAGCTGGT-3P EcoRI
53-R4 5P-TAGTGAATTCTCAGGGCAGCTCGTGGTGAGGCTC-3P EcoRI
aThe enzyme recognition sites are underlined. The translation initiation codons and complementary sequences of stop codons are shown in boldface
letters.
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analysis. The result revealed that NS3vC, but not NS3vNvC-
1, formed a complex with mt-p53 (data not shown).
3.2. Even in the presence of NS4A, NS3 forms a complex with
wt-p53
NS3 has been known to form a stable complex with NS4A.
Therefore, we examined the e¡ect of NS4A on NS3-p53 com-
plex formation. NS3vC, NS4A and wt-p53 were co-expressed,
and immunoprecipitation analysis was performed. Anti-NS3
monoclonal antibody co-precipitated both wt-p53 and NS4A
with NS3vC, although the same monoclonal antibody did not
co-precipitate wt-p53 or NS4A in the absence of NS3vC (Fig.
3). This result con¢rmed our previous immuno£uorescence
observation that NS3 was co-localized with wt-p53 in the
presence of NS4A, though in fewer occasions than in the
absence of NS4A [17]. Taken together, these results indicate
that, even in the presence of NS4A, NS3 can form a complex
with wt-p53.
3.3. The wt-p53-binding site of NS3 is di¡erent from the
NS4A-binding site
To look into the relationship between NS3-p53 complex
and NS4A, we examined the binding sites of NS3 against
wt-p53 and NS4A. A stretch of N-terminal 28 aa of NS3
has been shown to be important for binding to NS4A [5,8].
Therefore, we constructed a plasmid to express NS3vNvC-2,
in which the N-terminal 28 aa were deleted (Fig. 1).
NS3vNvC-2 and wt-p53 were co-expressed, and immunopre-
cipitation analysis was performed. Each of anti-NS3 and anti-
p53 monoclonal antibodies precipitated both NS3vNvC-2
and wt-p53 (Fig. 4A), clearly demonstrating complex forma-
tion between the two proteins. On the other hand, no complex
formation was observed between NS3vNvC-2 and NS4A
(Fig. 4B, lanes 2 and 3), while NS3vC formed a complex
with NS4A under the same conditions (Fig. 4B, lanes 5 and
6). These results strongly suggest that the wt-p53-binding site
is di¡erent from the NS4A-binding site, and are in good
agreement with the observation that, even in the presence of
NS4A, NS3 formed a complex with wt-p53 (Fig. 3). Our re-
sults, taken together, also suggest that wt-p53-binding site is
located in a portion near the N-terminus of NS3 between aa
1055^1200.
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Fig. 2. Complex formation of NS3 with wt-p53. Lysates of cells expressing wt-p53 and NS3F (A), NS3vC (B) or NS3vNvC-1 (C) were immu-
noprecipitated with normal mouse IgG (lane 1), anti-NS3 (lane 2) or anti-p53 monoclonal antibody (lane 3). Immunocomplex was separated by
SDS-PAGE and analyzed by autoradiography.
Fig. 3. The e¡ect of NS4A on the complex formation between NS3
and wt-p53. Lysates of cells expressing NS3vC, wt-p53 and NS4A
(lanes 1 and 2) or lysates of cells expressing wt-p53 and NS4A (lane
3) were immunoprecipitated with normal mouse IgG (lane 1) or
anti-NS3 monoclonal antibody (lanes 2 and 3). Immunocomplex
was separated by SDS-PAGE and analyzed by autoradiography.
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3.4. The portion near the N-terminus of NS3 (aa 1055^1200)
forms a complex with wt-p53
To directly assess the possibility that the portion near the
N-terminus of NS3 (aa 1055^1200) is important for the asso-
ciation between NS3 and p53, NS3vNvC-3FLAG (Fig. 1A)
was co-expressed with wt-p53. As shown in Fig. 5,
NS3vNvC-3FLAG and wt-p53 were co-precipitated with
each of the respective monoclonal antibodies, suggesting
that the portion of NS3 between aa 1055 and 1200 is involved
in the complex formation with wt-p53.
3.5. A portion near the C-terminus of wt-p53 is involved in the
complex formation with NS3
To determine the portion of wt-p53 involved in the complex
formation with NS3, we performed deletion mutational anal-
ysis of wt-p53. wt-p53 has been shown to have various func-
tional domains, such as transactivation [23], DNA binding
[24] and oligomerization domains [25] (Fig. 1B). We focused
on transactivation and oligomerization domains of wt-p53.
We ¢rst examined wt-p53vN40 and wt-p53vC300, which
lack the transactivation and oligomerization domains, respec-
tively (Fig. 1B). When co-expressed with NS3vCFLAG, wt-
p53vN40 was co-precipitated with anti-FLAG monoclonal
antibody, and similarly, NS3vCFLAG was co-precipitated
with anti-p53 monoclonal antibody (Fig. 6A, lanes 2 and 3).
When wt-p53vC300 was expressed with NS3vCFLAG, how-
ever, co-precipitation of the two proteins was not observed
(Fig. 6A, lanes 5 and 6). To determine the important portion
of wt-p53 in more detail, expression plasmids for wt-
p53vC318 and wt-p53vC360 were constructed (Fig. 1B).
When wt-p53vC360 was expressed with NS3vCFLAG, co-
precipitation of the two proteins was still clearly observed
(Fig. 6B, lanes 1 and 2). However, when wt-p53vC318 was
expressed with NS3vCFLAG, co-precipitation of the two
molecules became very faint (Fig. 6B, lanes 3 and 4). These
results suggest that a portion near the C-terminus of wt-p53
(aa 301^360) is important for complex formation between
NS3 and wt-p53. Since the region between aa 301 and 360
has been shown to include oligomerization domain of wt-p53
[25], NS3 might interfere with wt-p53 oligomerization.
In conclusion, our present data demonstrate that NS3 can
form a complex with p53. The complex formation is likely to
result from direct interaction between the two molecules, be-
cause no speci¢c band other than NS3s and wt-p53s was
detected in the co-immunoprecipitation analysis. In the
present study, NS3s and wt-p53s were expressed abundantly
by using a strong expression system [19]. We do not know, at
present, whether or not the same interaction takes place in
HCV-infected cells. In this connection, Errington et al. [26]
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Fig. 4. Comparison between the wt-p53-binding site and NS4A-binding site of NS3. A: Lysates of cells expressing NS3vNvC-2 and wt-p53
were immunoprecipitated with normal mouse IgG (lane 1), anti-NS3 (lane 2) or anti-wt-p53 monoclonal antibody (lane 3). Immunocomplex
was separated by SDS-PAGE and analyzed by autoradiography. B: Lysates of cells expressing NS4A and NS3vNvC-2 (lanes 1^3) or NS3vC
(lanes 4^6) were immunoprecipitated with normal mouse IgG (lanes 1 and 4), anti-NS3 (lanes 2 and 5) or anti-NS4A monoclonal antibody
(lanes 3 and 6).
Fig. 5. Complex formation between wt-p53 and a portion near the
N-terminus of NS3 (aa 1055^1200). Lysates of cells expressing
NS3vNvC-3FLAG and wt-p53 were immunoprecipitated with nor-
mal mouse IgG (lane 1), anti-FLAG (lane 2) or anti-p53 monoclo-
nal antibody (lane 3). Immunocomplex was separated by SDS-
PAGE and analyzed by autoradiography.
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reported prominent nuclear accumulation of NS3 in a minor
proportion of HCV-infected hepatocytes in patients. The au-
thors did not test the expression of p53 in these hepatocytes.
It would be worthwhile to examine for the possible interaction
between NS3 and p53 in such HCV-infected hepatocytes.
Recently, NS3 was reported to transform NIH3T3 cells [14]
and inhibit actinomycin D-induced apoptosis [16]. These re-
sults imply the possibility that NS3 interferes with the func-
tion of p53, which would eventually lead to malignant trans-
formation of the cells.
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Fig. 6. Complex formation between NS3vCFLAG and various forms of wt-p53. A: Lysates of cells expressing NS3vCFLAG and wt-p53vN40
(lanes 1^3) or wt-p53vC300 (lanes 4^6) were immunoprecipitated with normal mouse IgG (lanes 1 and 4), anti-FLAG (lanes 2 and 5) or anti-
p53 monoclonal antibody (lanes 3 and 6). Immunocomplex was separated by SDS-PAGE and analyzed by autoradiography. B: Lysates of cells
expressing NS3vCFLAG and wt-p53vC360 (lanes 1 and 2), wt-p53vC318 (lanes 3 and 4) or wt-p53vC300 (lanes 5 and 6) were immunoprecipi-
tated with anti-FLAG (lanes 1, 3 and 5) or anti-p53 monoclonal antibody (lanes 2, 4 and 6).
S. Ishido, H. Hotta/FEBS Letters 438 (1998) 258^262262
